language Türkçe
Article 2023 · 10 citations

Design, synthesis, a-glucosidase inhibition, pharmacokinetic, and cytotoxic studies of new indole-carbohydrazide-phenoxy-<i>N</i>-phenylacetamide derivatives

Hamedifar, Haleh, Mohammadi-Khanaposhtani, Maryam, Sherafati, Maedeh, Noori, Milad, Moazam, Ali, Hosseini, Samanesadat, Larijani, Bagher, Hajimiri, Mir H., Mahdavi, Mohammad, Erdogan, Mehmet K., Gundogdu, Ramazan, Kirici, Mahinur, Taslimi, Parham, Gulcin, Ilhami

Abstract

A new series of indole-carbohydrazide-phenoxy-N-phenylacetamide derivatives 7a-l were designed, synthesized, and screened for their alpha-glucosidase inhibitory abilities and cytotoxic effects. The results obtained in the alpha-glucosidase inhibition assay indicated that most of the synthesized derivatives displayed good to moderate inhibitory abilities (K-i values ranging from 14.65 +/- 2.54 to 37.466 +/- 6.46 mu M) when compared with the standard drug acarbose ( K-i = 42.38 +/- 5.73 mu M). Among them, 2-mehoxy-phenoxy derivatives 7l and 7h with 4-nitro and 4-chloro substituents on the phenyl ring of the N-phenylacetamide moiety, respectively, displayed the most inhibition effects. The inhibitory mechanism of these compounds was investigated by molecular docking studies. The in vitro cytotoxicity assay showed that only one compound, 2-methoxy-phenoxy derivative 7k with a 4- bromo substituent on the phenyl ring of the N-phenylacetamide moiety, exhibited moderate cytotoxicity against the human non-small-cell lung cancer cell line A549 and the rest of the compounds show almost no cytotoxicity. Further cytotoxic evaluations were also performed on compound 7k. The in silico pharmacokinetic study predicted that the selected compounds 7l and 7h are likely to be orally active.

Keywords
indole-carbohydrazide phenoxy-N-phenylacetamide synthesis alpha-glucosidase inhibitors ALPHA-GLUCOSIDASE APOPTOSIS INDUCTION ASSAY
WoS Categories
Chemistry, Medicinal Chemistry, Multidisciplinary Pharmacology & Pharmacy
Sustainable Development Goals
Citation
Journal
ARCHIV DER PHARMAZIE
Year
2023
Volume
356
Issue
6
ISSN
0365-6233
eISSN
1521-4184
DOI
10.1002/ardp.202200571
WoS UID
WOS:000964515400001
Open via DOI